Evolving customer expectations and business needs have fueled a digital transformation in China, marked by the integration of cloud computing and artificial intelligence ("AI") into companies' operations. "To survive in this new world, businesses must learn to observe, think, and operate differently," reads Deloitte China's webpage about digital transformation (https://nnw.fm/8rH63). "Digital transformation, the cross-disciplinary power comprising digital, analytics, cloud, cybersecurity, and regulatory compliance, is about embracing digital disruption and unlocking exponential value." Interestingly, Infobird Software (NASDAQ: IFBD), a Software-as-a-Service (SaaS) company offering AI-enabled end-to-end customer engagement solutions in China, has packaged the aspects of digital transformation mentioned above, i.e., cloud computing, analytics, cybersecurity, and digital, into its robust proprietary solutions and is using them to help companies around China adapt to the changing times and transform digitally. IFBD's customer engagement solutions, which integrate the needs of both the customers and the businesses into a single platform, stimulate companies' market performance and growth and enable them to improve their infrastructure.

The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving. Predictive Oncology (NASDAQ: POAI) (POAI Profile) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer. The company is leveraging this unique database through Artificial Intelligence to provide the actionable insights needed to drive pharma R&D programs and improve patient outcomes. A data asset like this typically takes at least five years to fully validate and most competitors are only in the early stages of the process.

Predictive Oncology Inc. (NASDAQ: POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments. Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic's CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

Related Editorial The rise of artificial intelligence is fast disrupting the financial universe and establishing new paradigms of understanding and action. Computers now drive market velocity, and because the volume of available financial information has expanded exponentially over the last few decades, machines have become indispensable to deciphering these mountains of megabytes in order to create clear-cut actionable intelligence. Given the large data sets and quantitative nature of the modern-day financial services sector, artificial intelligence (AI) has innumerable applications that are poised to revolutionize the industry over the next few years. AI saves companies time and money through the use of algorithms to generate insights, improve customer service and make calculated performance predictions. Because of the ability to foresee market trends and deliver analysis and insights far better than humans, information behemoths and financial titans such as S&P Global Inc. (NYSE: SPGI), Euronext NV (OTC: EUXTF), The Blackstone Group, L.P. (NYSE: BX) and Thomson Reuters Corp (NYSE: TRI) are integrating and increasingly acquiring machine-learning, artificial intelligence technologies such as those provided by AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) (ATIXF Profile), which offers investors a compelling opportunity to participate in this industry shift.

The rise of artificial intelligence is fast disrupting the financial universe and establishing new paradigms of understanding and action. Computers now drive market velocity, and because the volume of available financial information has expanded exponentially over the last few decades, machines have become indispensable to deciphering these mountains of megabytes in order to create clear-cut actionable intelligence. Given the large data sets and quantitative nature of the modern-day financial services sector, artificial intelligence (AI) has innumerable applications that are poised to revolutionize the industry over the next few years. AI saves companies time and money through the use of algorithms to generate insights, improve customer service and make calculated performance predictions. Because of the ability to foresee market trends and deliver analysis and insights far better than humans, information behemoths and financial titans such as S&P Global Inc. (NYSE: SPGI), Euronext NV (OTC: EUXTF), The Blackstone Group, L.P. (NYSE: BX) and Thomson Reuters Corp (NYSE: TRI) are integrating and increasingly acquiring machine-learning, artificial intelligence technologies such as those provided by AnalytixInsight Inc. (TSX-V: ALY) (OTC: ATIXF) (ATIXF Profile), which offers investors a compelling opportunity to participate in this industry shift.